Cargando…

Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy

Ovarian carcinoma is one of the most common causes for cancer death in women; lack of early diagnosis and acquired resistance to platinum-based chemotherapy account for its poor prognosis and high mortality rate. As with other cancer types, ovarian cancer is characterized by dysregulated signaling p...

Descripción completa

Detalles Bibliográficos
Autores principales: Romagnoli, Alice, Maracci, Cristina, D’Agostino, Mattia, Teana, Anna La, Marino, Daniele Di
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094073/
https://www.ncbi.nlm.nih.gov/pubmed/35582305
http://dx.doi.org/10.20517/cdr.2021.20
_version_ 1784705465330958336
author Romagnoli, Alice
Maracci, Cristina
D’Agostino, Mattia
Teana, Anna La
Marino, Daniele Di
author_facet Romagnoli, Alice
Maracci, Cristina
D’Agostino, Mattia
Teana, Anna La
Marino, Daniele Di
author_sort Romagnoli, Alice
collection PubMed
description Ovarian carcinoma is one of the most common causes for cancer death in women; lack of early diagnosis and acquired resistance to platinum-based chemotherapy account for its poor prognosis and high mortality rate. As with other cancer types, ovarian cancer is characterized by dysregulated signaling pathways and protein synthesis, which together contribute to rapid cellular growth and invasiveness. The mechanistic/mammalian target of rapamycin (mTOR) pathway represents the core of different signaling pathways regulating a number of essential steps in the cell, among which protein synthesis and the eukaryotic initiation factor 4E (eIF4E), the mRNA cap binding protein, is one of its downstream effectors. eIF4E is a limiting factor in translation initiation and its overexpression is a hallmark in many cancers. Because its action is regulated by a number of factors that compete for the same binding site, eIF4E is an ideal target for developing novel antineoplastic drugs. Several inhibitors targeting the mTOR signaling pathway have been designed thus far, however most of these molecules show poor stability and high toxicity in vivo. This minireview explores the possibility of targeting mTOR and eIF4E proteins, thus impacting on translation initiation in ovarian cancer, describing the most promising experimental strategies and specific inhibitors that have been shown to have an effect on other kinds of cancers.
format Online
Article
Text
id pubmed-9094073
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher OAE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-90940732022-05-16 Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy Romagnoli, Alice Maracci, Cristina D’Agostino, Mattia Teana, Anna La Marino, Daniele Di Cancer Drug Resist Review Ovarian carcinoma is one of the most common causes for cancer death in women; lack of early diagnosis and acquired resistance to platinum-based chemotherapy account for its poor prognosis and high mortality rate. As with other cancer types, ovarian cancer is characterized by dysregulated signaling pathways and protein synthesis, which together contribute to rapid cellular growth and invasiveness. The mechanistic/mammalian target of rapamycin (mTOR) pathway represents the core of different signaling pathways regulating a number of essential steps in the cell, among which protein synthesis and the eukaryotic initiation factor 4E (eIF4E), the mRNA cap binding protein, is one of its downstream effectors. eIF4E is a limiting factor in translation initiation and its overexpression is a hallmark in many cancers. Because its action is regulated by a number of factors that compete for the same binding site, eIF4E is an ideal target for developing novel antineoplastic drugs. Several inhibitors targeting the mTOR signaling pathway have been designed thus far, however most of these molecules show poor stability and high toxicity in vivo. This minireview explores the possibility of targeting mTOR and eIF4E proteins, thus impacting on translation initiation in ovarian cancer, describing the most promising experimental strategies and specific inhibitors that have been shown to have an effect on other kinds of cancers. OAE Publishing Inc. 2021-05-11 /pmc/articles/PMC9094073/ /pubmed/35582305 http://dx.doi.org/10.20517/cdr.2021.20 Text en © The Author(s) 2021. https://creativecommons.org/licenses/by/4.0/© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Romagnoli, Alice
Maracci, Cristina
D’Agostino, Mattia
Teana, Anna La
Marino, Daniele Di
Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy
title Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy
title_full Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy
title_fullStr Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy
title_full_unstemmed Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy
title_short Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy
title_sort targeting mtor and eif4e: a feasible scenario in ovarian cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094073/
https://www.ncbi.nlm.nih.gov/pubmed/35582305
http://dx.doi.org/10.20517/cdr.2021.20
work_keys_str_mv AT romagnolialice targetingmtorandeif4eafeasiblescenarioinovariancancertherapy
AT maraccicristina targetingmtorandeif4eafeasiblescenarioinovariancancertherapy
AT dagostinomattia targetingmtorandeif4eafeasiblescenarioinovariancancertherapy
AT teanaannala targetingmtorandeif4eafeasiblescenarioinovariancancertherapy
AT marinodanieledi targetingmtorandeif4eafeasiblescenarioinovariancancertherapy